Evogene LTD

Leon Recanati, a Director of Evogene Ltd., purchased 460,000 shares of common stock on August 11, 2026 for $0.64 per share.

Evogene Ltd. shareholders Kfir Silberman and Eli Zamir, along with their affiliated entities, have announced their intention to launch a special tender offer to acquire a significant stake in the company.

Evogene Ltd. announces an amendment to its Schedule 13D filing, detailing Leon Recanati's acquisition of an additional 1,260,000 ordinary shares through at-the-market offerings.

L.I.A. Pure Capital and Invest-Pro criticize Evogene's track record and urge shareholders to vote for their board nominees.

L.I.A. Pure Capital Ltd. and associated entities have amended their Schedule 13D filing to report an increase in their beneficial ownership of Evogene Ltd. ordinary shares and ADSs.

Leon Recanati, a board member of Evogene Ltd., has increased his beneficial ownership to 8.6% by acquiring an additional 460,000 ordinary shares.

Leon Recanati, a board member and significant shareholder, has disclosed an increased stake in Evogene Ltd. and declared his intention to vote in favor of the current board's nominees in an upcoming contested director election.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 713,539 ordinary shares, representing 4.99% of Evogene Ltd.'s outstanding shares.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Evogene Ltd.'s ordinary shares as of March 31, 2026.